

GALDERMA Policy on Expanded Access Program

At this time, GALDERMA does not have an expanded access program that allows patients to have access to the company's investigational therapies outside of clinical trials or prior to FDA approval. GALDERMA believes clinical trials are the most appropriate way for patients to access investigational medicines developed by GALDERMA. In these trials, the safety and efficacy of investigational medicines are rigorously assessed by GALDERMA and the relevant regulatory agencies in order to understand the medicine's benefits, risks, and appropriate use, including whether or not it should be approved as a therapy for its intended use. Obtaining regulatory approval is the best way to bring safe and effective medicines to the greatest number of patients who may benefit from treatment.

GALDERMA may update this policy as drug development programs are progressing and reassess the approach to expanded access programs.

Should patients, families, or physicians have any questions, please contact our Medical Information department by email at Medicalinfo-trials@galderma.com.